Carregant...
真实世界吡咯替尼治疗HER2阳性转移性乳腺癌的疗效及安全性
OBJECTIVE: Pyrotinib, a novel irreversible pan-ErbB receptor tyrosine kinase inhibitor, showed promising antitumor activity and acceptable tolerability in phase Ⅱ and phase Ⅲ randomized clinical trials. We assessed the activity and safety of oral pyrotinib for human epidermal growth factor receptor...
Guardat en:
| Publicat a: | Beijing Da Xue Xue Bao Yi Xue Ban |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
北京大学学报(医学版)编辑部
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7433442/ https://ncbi.nlm.nih.gov/pubmed/32306007 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.19723/j.issn.1671-167X.2020.02.010 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|